Sangamo Therapeutics Announces Third Quarter 2023 Conference Call and Webcast

Contributed by: Business Wire

Logo

Tags

Health

Other Science

General Health

Research

Science

Pharmaceutical

Biotechnology

Sangamo Therapeutics, Inc.

More Like This

Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering

Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)

Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Silence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024

PR Newswire associated0

Jazz Pharmaceuticals to Report 2023 Third Quarter Financial Results on November 8, 2023

PR Newswire associated0

Jazz Pharmaceuticals to Report 2024 Third Quarter Financial Results on November 6, 2024

Sangamo Therapeutics Announces Global Epigenetic Regulation and Capsid Delivery License Agreement with Genentech to Develop Novel Genomic Medicines for Neurodegenerative Diseases

Exscientia to Report Third Quarter 2023 Financial Results on November 9, 2023